Zebinix(R) Now Available in Greece (y 2)

-- Zonegran(R) (zonisamide) as adjunctive therapy in adult patients with partial-onset seizures, with or without secondary generalisation

-- Zebinix(R) (eslicarbazepine acetate) as adjunctive therapy in adult patients with partial-onset seizures, with or without secondary generalization

-- Inovelon(R) (rufinamide) for the treatment of seizures associated with Lennox-Gastaut Syndrome

About Eisai

Eisai is one of the world's leading R&D-based pharmaceutical companies, that has defined its corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call human health care (hhc).

Eisai concentrates its R&D activities in three key areas:

-- Integrative Neuroscience: Alzheimer's disease, multiple sclerosis, neuropathic pain, epilepsy, depression, etc

-- Integrative Oncology: Anticancer therapies; tumour regression, tumour suppression, antibodies, etc and Supportive cancer therapies; pain relief, nausea, etc

-- Vascular/Immunological Reaction: Acute coronary syndrome, atherothrombotic disease, sepsis, rheumatoid arthritis, psoriasis, Crohn's disease, etc

With operations in the U.S., Asia, Europe and its domestic home market of Japan, we employ more than 10,000 people worldwide, and reported consolidated sales of over GBP3.53 billion in FY2007, an increase of 8.9% year on year. In Europe, Eisai undertakes sales and marketing operations in over 20 markets, including the United Kingdom, France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark, Finland, Norway, Portugal, Iceland, Czech Republic, Hungary, and Slovakia.

For further information please visit our web site http://www.eisai.co.jp

About BIAL

Founded in 1924, BIAL is an international pharmaceutical group with products available in more than 40 countries throughout four continents. BIAL is a privately held Portuguese research based pharmaceutical company and the largest Portuguese pharmaceutical company, based in S. Mamede do Coronado, Portugal, responsible for the research and development of eslicarbazepine acetate (Zebinix(R)).

It is the partner of choice for many companies, having a strong presence in the Iberian peninsula as well as in over 10 countries in Latin America and in around 20 French or Portuguese speaking African countries.

BIAL is strongly committed to therapeutic innovation investing more than 20% of its turnover in research and development every year. Key research areas for BIAL are the central nervous system, the cardiovascular system and allergen immunotherapy. BIAL currently has several other innovative programs under development, which the company expects to bring to the market within the next years, thereby strengthening its position throughout Europe.

Further information about BIAL can be found at http://www.bial.com

References

[1] Zebinix 800mg tablets - Summary of Product Characteristics (SPC): Last updated 10 January 2011) Available from URL: http://www.medicines.org.uk/emc/medicine... (Accessed 29 March 2011)

[2] Cramer JA, Elger C, Halasz P, et al, editors. An evaluation of quality of life and depressive symptoms during long-term treatment with eslicarbazepine acetate: BIA-2093-301 study [abstract 3.197]. American Epilepsy Society Congress; 2008 5-9 December; Seattle, WA.

[3] Greek Association Against Epilepsy. What is epilepsy? Available from URL: http://www.greece-epilepsy.com

(Accessed 28 February 2011)

[4] Kwan P, Brodie MJ Early identification of refractory epilepsy. New England Journal of Medicine 2000; 342: 314-9.

[5] Eisai Europe Ltd. Data on file. Zebinix PSUR of period 22-Apil-2010 to 21-October-2010

[6] Epilepsy Research UK. What is Epilepsy? Fact sheet. Avaiable from URL: http://www.epilepsyresearch.org.uk/about... (accessed March 16 2011)

[7] Epilepsy Action. Describing Seizure Types. Avaiable at URL http://www.epilepsy.org.uk/info/seizures... (Accessed March 16 2011)

[8] NHS Choices. Symptoms of Epilepsy. Available at URL http://www.nhs.uk/Conditions/Epilepsy/Pa... (Accessed March 16 2011)

[9] Topamax Summary of Product Characteristics. Available at: http://www.medicines.org.uk/emc/medicine... (Accessed March 18 2011)

[10] Carbamazepine Summary of Product Characteristics. Available at: http://www.medicines.org.uk/EMC/medicine... 200mg%2c+Tegretol+Tablets+100mg%2c+200mg%2c+400mg/ (Accessed March 18 2011)

[11] Oxcarbazepine Summary of Product Characteristics. Available at: http://www.medicines.org.uk/emc/medicine... (Accessed March 18 2011)

[12] Elger C, Halász P, Maia J et al. Efficacy and safety of eslicarbazepine acetate as adjunctive treatment in adults with refractory partial-onset seizures: A randomized, double-blind, placebo-controlled, parallel-group phase III study. Epilepsia 2009; 50(3):454-463.

[13] Almeida L, Soares-da-Silva P. Eslicarbazepine acetate (BIA 2-093). Neurotherapeutics. 2007 Jan;4(1):88-96.

[14] Elger et al. Eslicarbazepine Acetate: A Double-blind, Add-on Placebo-controlled Exploratory Trial in Adult Patients with Partial-onset seizures. Epilepsia, 48(3):497-504, 2007

[15] Ben-Menachem E, Gabbai A, Hufnagel A, Maia J, Almeida L, Soares-da-Silver P. Eslicarbazepine acetate as adjunctive therapy in adult patients with partial epilepsy; Epilepsy Research 2010;89:278-285.

[16] Lopes-Lima J, Gil-Nagel A, Maia J et al. Efficacy and safety of eslicarbazepine acetate as add-on treatment in adults with refractory partial-onset seizures: BIA-2093-303 Study. Poster presented at the 8th European Congress on Epileptology, 21-25 September 2008, Berlin, Germany.

[17] Cramer J, Elger C, Halász P et al. Improvement in quality-of-life and depressive symptoms during long term treatment with eslicarbazepine acetate: BIA-2093-301 study (Abstract No. 3.197). Epilepsia. 2008;49(Suppl. 7):426-7.

[18] Soares-da-Silva P, Martins-da-Silva A, Gabbai AA et al. Improvement in quality-of-life and depressive symptoms during long-term treatment with eslicarbazepine acetate: BIA-2093-302 study (Abstract No. 3.254). Epilepsia. 2008;49(7):455-6.

[19] Pereira H, Lopes-Lima J, Gil-Nagel A et al. Improvement in quality-of-life and depressive symptoms during long-term treatment with eslicarbazepine acetate: BIA-2093-303 study (Abstract No. 3.240). Epilepsia. 2008;49(Suppl. 7):446-8.

[20] Cramer J, Maia J, Almeida L, et al. Quality-of-life improvement during long-term treatment with eslicarbazepine acetate (Abs tract No. T278). Epilepsia. 2009;50(Suppl. 4):124.

[21] Hodoba D, Cz,onkowska A, Cramer J, et al. Depressive symptoms improvement during long-term treatment with eslicarbazepine acetate (Abstract No. T286). Epilepsia. 2009;50(Suppl. 4):126.

[22] Halász P, Elger C, Guekht A, et al. Long-term-treatment of partial epilepsy with eslicarbazepine acetate (ESL): results of a one-year open-label extension to study BIA-2093- 301 (Abstract No. 3.213). Epilepsia. 2008;49(Suppl. 7):435-6.

[23] Lopes-Lima J, Gil-Nagel A, Maia J, et al. Long-term treatment of partial epilepsy with eslicarbazepine acetate (ESL): results of a one-year open-label extension of study BIA-2093-303 (Abstract No. 3.227). Epilepsia. 2008;49(Suppl. 7):441-2.

[24] Gabbai A, Ben-Menachem E, Maia J, et al. Long-term treatment of partial epilepsy with eslicarbazepine acetate (ESL): results of a one-year open-label extension of study BIA-2093- 302 (Abstract No. 3.208). Epilepsia. 2008;49(Suppl. 7):432-3.

CONTACT: For further information please contact: Benjamyn Tan / HelenSwift, Tonic Life Communications, +44(0)20-7798-9262,benjamyn.tan@toniclc.com / helen.swift@toniclc.com; Eisai Europe Ltd -Cressida Robson: +44(0)845-676-5318